Skip to main content
Premium Trial:

Request an Annual Quote

Lumera Licenses Helix Biopharma Technology in Bid to Enter Protein Array Market

NEW YORK, Jan. 25 (GenomeWeb News) - Lumera said today that it has acquired the exclusive rights to protein surface chemistry from Helix Biopharma in order to further its development of a proteomic microarray.

 

Lumera said it will combine Helix Biopharma's Heterodimer Protein Technology with its own NanoCapture Array technology. The integrated technologies will allow Lumera to produce and capture proteins on a silicon surface while keeping the proteins fully functional, the company said.

 

Financial terms of the agreement were not provided.

 

The company said it has already produced prototype chips using the combined technologies, and carried out enzymatic, binding, and proteomic studies.

 

Lumera said it plans to begin shipping a product based on the technology later this year.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.